Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

Przemysław Holko,Paweł Kawalec,Andrzej Pilc

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist

2018

Przemysław Holko
Paweł Kawalec
Andrzej Pilc

Objective The aim was to evaluate the cost-effectiveness of Crohn’s disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs).

Keywords:

Ustekinumab
Intensive care medicine
Tumor necrosis factor alpha
Cost-effectiveness analysis
Disease
Vedolizumab
Cancer research
Crohn's disease
Medicine
Monoclonal
Antagonist
Gastroenterology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations